Company

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio
IntraBioRare / orphan disease drugs

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Shionogi & Co., Ltd. (TYO: 4507) announced a definitive agreement to acquire IntraBio, a biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative diseases, for an upfront cash consideration…

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AstraZenecaCancer

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

AlectorGlaxoSmithKline

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

ADC / XDCClinical trial approval / initiation

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

HKG: 6622Ophthalmology

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Show More